What do systematic reviews say?

Continuous platinum infusion vs bolus platinum infusion

The review found no eligible studies for this question.

• Different infusion durations for preventing platinum‐induced hearing loss in children with cancer 2020 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Platinum‐containing chemotherapy vs chemotherapy without platinum

The review found no eligible studies for this question.

• Platinum‐based chemotherapy for early triple‐negative breast cancer 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Non‐platinum therapies vs platinum combination

• Chemotherapy for advanced non‐small cell lung cancer in the elderly population 2015 · Cochrane Headline outcomes only
  no estimate extracted
  5 studies · 5 participants
  GRADE not reported

Non‐platinum single‐agent vs non‐platinum combination treatment

• Chemotherapy for advanced non‐small cell lung cancer in the elderly population 2015 · Cochrane Headline outcomes only
  no estimate extracted
  2 studies · 2 participants
  GRADE not reported

Summary of findings table ‐ Platinum‐sensitive recurrent EOC: PARPi monotherapy vs chemotherapy alone

• Poly(ADP‐ribose) polymerase (PARP) inhibitors for the treatment of ovarian cancer 2022 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 229 participants
  Low

Summary of findings table ‐ Platinum‐resistant recurrent EOC: PARPi monotherapy vs chemotherapy alone

The review found no eligible studies for this question.

• Poly(ADP‐ribose) polymerase (PARP) inhibitors for the treatment of ovarian cancer 2022 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Summary of findings table ‐ Platinum‐sensitive recurrent EOC: PARPi with chemotherapy vs chemotherapy alone

The review found no eligible studies for this question.

• Poly(ADP‐ribose) polymerase (PARP) inhibitors for the treatment of ovarian cancer 2022 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Summary of findings table ‐ Platinum‐sensitive recurrent EOC: PARPi monotherapy vs placebo (maintenance therapy)

• Poly(ADP‐ribose) polymerase (PARP) inhibitors for the treatment of ovarian cancer 2022 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 339 participants
  Moderate

Sodium thiosulfate vs no otoprotective intervention

The review found no eligible studies for this question.

• Medical interventions for the prevention of platinum‐induced hearing loss in children with cancer 2019 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Amifostine vs no otoprotective intervention

The review found no eligible studies for this question.

• Medical interventions for the prevention of platinum‐induced hearing loss in children with cancer 2019 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Summary of findings 2: PLD alone vs other conventional chemotherapy

The review found no eligible studies for this question.

• Pegylated liposomal doxorubicin for relapsed epithelial ovarian cancer 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Summary of findings 1: PLD with chemotherapy vs PLD alone

The review found no eligible studies for this question.

• Pegylated liposomal doxorubicin for relapsed epithelial ovarian cancer 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Bevacizumab plus chemotherapy vs chemotherapy alone

The review found no eligible studies for this question.

• Angiogenesis inhibitors for the treatment of epithelial ovarian cancer 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Amifostine vs no otoprotective intervention

The review found no eligible studies for this question.

• Medical interventions for the prevention of platinum‐induced hearing loss in children with cancer 2019 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Sodium thiosulfate vs no otoprotective intervention

The review found no eligible studies for this question.

• Medical interventions for the prevention of platinum‐induced hearing loss in children with cancer 2019 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Summary of findings 1: PLD with chemotherapy vs alternative combination chemotherapy

• Pegylated liposomal doxorubicin for relapsed epithelial ovarian cancer 2023 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 608 participants
  Low

Chemotherapy with bevacizumab followed by bevacizumab maintenance vs chemotherapy alone

• Angiogenesis inhibitors for the treatment of epithelial ovarian cancer 2023 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 486 participants
  Low

Chemotherapy with TKI followed by TKI maintenance vs chemotherapy alone

• Angiogenesis inhibitors for the treatment of epithelial ovarian cancer 2023 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 146 participants
  Low

Chemotherapy with TKI vs chemotherapy alone

Chemotherapy with TKI showed no clear difference in quality of life (QoL) compared with chemotherapy alone (low certainty).

• Angiogenesis inhibitors for the treatment of epithelial ovarian cancer 2023 · Cochrane Headline outcomes only
  no estimate extracted
  3 studies · 164 participants
  Low

Pembrolizumab vs chemotherapy alone

Pembrolizumab may leads to higher quality of life (Change from baseline to week 15) compared with chemotherapy (low certainty).

• Pembrolizumab monotherapy versus chemotherapy for treatment of advanced urothelial carcinoma with disease progression… 2018 · Cochrane Headline outcomes only
  MD 9.05 [4.61, 13.5]
  1 study · 519 participants
  Low